1393178-04-5Relevant articles and documents
Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor
Swanson, Devin M.,Savall, Brad M.,Coe, Kevin J.,Schoetens, Freddy,Koudriakova, Tatiana,Skaptason, Judith,Wall, Jessica,Rech, Jason,Deng, Xiahou,De Angelis, Meri,Everson, Anita,Lord, Brian,Wang, Qi,Ao, Hong,Scott, Brian,Sepassi, Kia,Lovenberg, Timothy W.,Carruthers, Nicholas I.,Bhattacharya, Anindya,Letavic, Michael A.
, p. 8535 - 8548 (2016)
The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of 1 (JNJ 54166060). 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism.
